Genomic landscape of follicular lymphoma across a wide spectrum of clinical behaviors
Authors:
Open Access
- 30 March 2023
- journal article
- research article
- Published by Wiley in Hematological Oncology
- Vol. 41 (4) , 631-643
Abstract
While some follicular lymphoma (FL) patients do not require treatment or experience prolonged responses, others relapse early, and little is known about genetic alterations specific to patients with a particular clinical behavior. We selected 56 grade 1–3A FL patients according to their need of treatment or timing of relapse: never treated (n = 7), non‐relapsed (19), late relapse (14), early relapse or POD24 (11), and primary refractory (5). We analyzed 56 diagnostic and 12 paired relapse lymphoid tissue biopsies and performed copy number alteration (CNA) analysis and next generation sequencing (NGS). We identified six focal driver losses (1p36.32, 6p21.32, 6q14.1, 6q23.3, 9p21.3, 10q23.33) and 1p36.33 copy‐neutral loss of heterozygosity (CN‐LOH). By integrating CNA and NGS results, the most frequently altered genes/regions were KMT2D (79%), CREBBP (67%), TNFRSF14 (46%) and BCL2 (40%). Although we found that mutations in PIM1, FOXO1 and TMEM30A were associated with an adverse clinical behavior, definitive conclusions cannot be drawn, due to the small sample size. We identified common precursor cells harboring early oncogenic alterations of the KMT2D, CREBBP, TNFRSF14 and EP300 genes and 16p13.3‐p13.2 CN‐LOH. Finally, we established the functional consequences of mutations by means of protein modeling (CD79B, PLCG2, PIM1, MCL1 and IRF8). These data expand the knowledge on the genomics behind the heterogeneous FL population and, upon replication in larger cohorts, could contribute to risk stratification and the development of targeted therapies.Keywords
Funding Information
- Centro de Investigación Biomédica en Red de Cáncer (PROYE18020BEA)
This publication has 41 references indexed in Scilit:
- PepSite: prediction of peptide-binding sites from protein surfacesNucleic Acids Research, 2012
- Pim1 kinase is required to maintain tumorigenicity in MYC-expressing prostate cancer cellsOncogene, 2011
- Frequent mutation of histone-modifying genes in non-Hodgkin lymphomaNature, 2011
- Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profilesHaematologica, 2011
- Inactivating mutations of acetyltransferase genes in B-cell lymphomaNature, 2011
- International network of cancer genome projectsNature, 2010
- Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center originNature Genetics, 2010
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphomaNature, 2010
- Prognostic significance of secondary cytogenetic alterations in follicular lymphomasGenes, Chromosomes and Cancer, 2008
- Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science studyLeukemia & Lymphoma, 2008